Induction therapy CapeOX + BEV (N = 52) | Maintenance therapy Capecitabin + BEV (N = 45) | Reintoroduction therapy CapeOX + BEV (N = 29) | |
---|---|---|---|
Treatment cycle, times | |||
Median (range) | 4 (2–4) | 7 (1–8) | 5 (1–21) |
Median relative dose-intensity, % | |||
Oxaliplatin | 92.3 | - | 78.5 |
Capecitabin | 92.0 | 82.4 | 71.8 |
Bevacizumab | 96.6 | 92.0 | 91.0 |
Total dose of oxaliplatin, mg | |||
Median (range) | 1052 (470–4346) | ||
Time-to-treatment failuer, months | |||
Median (95% CI) | 9.9 (5.9–13.8) | ||
Post progression treatment, n (%) | |||
Second-line therapy | 46 | (88.5) | |
Anti-EGFR agents | 17 | (32.7) | |
Bevacizumab (BBP) | 35 | (67.3) | |
Resection of metastasis | 8 | (15.4) |